Related references
Note: Only part of the references are listed.Structures and mechanism of dipeptidyl peptidases 8 and 9, important players in cellular homeostasis and cancer
Breyan Ross et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis
Marian C. Okondo et al.
NATURE CHEMICAL BIOLOGY (2017)
Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC)
Zhiyuan Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure
Chintan N. Koyani et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death
Chintan N. Koyani et al.
BIOCHEMICAL PHARMACOLOGY (2016)
A Simplified, Langendorff-Free Method for Concomitant Isolation of Viable Cardiac Myocytes and Nonmyocytes From the Adult Mouse Heart
Matthew Ackers-Johnson et al.
CIRCULATION RESEARCH (2016)
Roles and regulation of protein phosphatase 2A (PP2A) in the heart
Ellen R. Lubbers et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2016)
Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation
Choon-Soo Lee et al.
SCIENTIFIC REPORTS (2016)
Identification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel electrophoresis
Hui Zhang et al.
FEBS JOURNAL (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Behavioral and molecular processing of visceral pain in the brain of mice: impact of colitis and psychological stress
Piyush Jain et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2015)
Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
Jacob A. Udell et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway
Yao Dai et al.
ACTA DIABETOLOGICA (2014)
Heart failure in the diabetic population - pathophysiology, diagnosis and management
Jacek Kasznicki et al.
ARCHIVES OF MEDICAL SCIENCE (2014)
15-deoxy-Δ12,14- PGJ2 promotes inflammation and apoptosis in cardiomyocytes via the DP2/MAPK/TNFα axis
Chintan N. Koyani et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
If blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes
Susanne Scheruebel et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2014)
Mechanisms of CaMKII activation in the heart
Jeffrey R. Erickson
FRONTIERS IN PHARMACOLOGY (2014)
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
John J. V. McMurray et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Diabetic cardiomyopathy: pathophysiology and clinical features
Takayuki Miki et al.
HEART FAILURE REVIEWS (2013)
Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity
P. A. Spagnuolo et al.
LEUKEMIA (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions
Toshimasa Shigeta et al.
CIRCULATION (2012)
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
Aiying Wang et al.
BMC Pharmacology & Toxicology (2012)
The dipeptidyl peptidase IV family in cancer and cell biology
Denise M. T. Yu et al.
FEBS JOURNAL (2010)
Electrophysiological remodeling in heart failure
Yanggan Wang et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs
Handan He et al.
DRUG METABOLISM AND DISPOSITION (2009)
Management of diabetes in cardiovascular patients
R. Peter et al.
HEART (2008)
Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation
William J. Metzler et al.
PROTEIN SCIENCE (2008)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV
C Olsen et al.
GENE (2002)
Protein phosphatase 2A and protein kinase Cα are physically associated and are involved in Pseudomonas aeruginosa-induced interleukin 6 production by mast cells
RTM Boudreau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Evolution and pathophysiology of chronic systolic heart failure
BE Bleske
PHARMACOTHERAPY (2000)
Calcium fluxes involved in control of cardiac myocyte contraction
DM Bers
CIRCULATION RESEARCH (2000)
Diastolic heart failure
L Mandinov et al.
CARDIOVASCULAR RESEARCH (2000)
Share Paper
